Vanguard Global Advisers
EWTX icon

Vanguard Global Advisers’s Edgewise Therapeutics EWTX Stock Holding History

Vanguard Global Advisers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
35,303
+5,977
+20% +$206K ﹤0.01% 1505
2026
Q1 		$924K Buy
+29,326
New +$846K ﹤0.01% 1699

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's EWTX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Edgewise Therapeutics (EWTX) stake by 20% in Q2 2026, buying an estimated $206K and bringing the position to 35,303 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Vanguard Global Advisers first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Vanguard Global Advisers held 35,303 shares of Edgewise Therapeutics worth $1.43M as of Q2 2026.
  • Vanguard Global Advisers bought 5,977 Edgewise Therapeutics shares in Q2 2026, an estimated $206K.
  • Edgewise Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1505 holding.
  • Vanguard Global Advisers first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.